|
|
 Aclairo® is pleased to announce the expansion of our preclinical services. Aclairo welcomes Jeri El-Hage, Ph.D, a recognized expert in FDA-regulated preclinical drug development, to our team of senior consultants.
Jeri El-Hage, Ph.D
Dr. El-Hage joins the consultants at Aclairo, bringing 18 years of preclinical regulatory experience, and allowing Aclairo® to offer more expertise in preclinical drug development than ever before. Leadership positions held in the Center for Drug Evaluation and Research at FDA include 6 years as supervisory pharmacologist in the Division of Metabolism and Endocrinology Products (DMEP), and 2 years as the Associate Director of Pharm/Tox for the Office of Drug Evaluation I. Her career in CDER also included 8 years as a pharmacology/toxicology reviewer in DMEP and 4 years as a reviewer in the Division of Reproductive and Urology Products.
Dr. El-Hage's most recent special projects and committee work within the FDA include:
- Carcinogenicity Assessment Committee member
- Pharmacokinetics/Toxicokinetics Subcommittee, co-chair. Thiscommittee recently published the draft guidance entitiled "Safety Testing of Drug Metabolites" in June, 2005.
- Recognized expert on the preclinical development and toxicity of Peroxisome Proliferator-Activated Receptor (PPAR) Agonists.
- Follow-on growth hormones and insulins
Dr. El-Hage has extensive preclinical experience with drugs indicated for diabetes, obesity, and dyslipidemia and peptide and protein hormone biologics. |
|
|
